Document is current
Any future updates will be listed below
-
Authors
Nagino, Ken
Sung, Jaemyoung
Midorikawa-Inomata, Akie
Eguchi, Atsuko
Nakao, Shintaro
Kobayashi, Hiroyuki
Inomata, Takenori https://orcid.org/0000-0003-3435-1055
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (25K20553, 23K16364, 24K19796)
Japan Agency for Medical Research and Development (JP20ek0410063)
- License Information
-
More Information
Article History
Received: 3 May 2025
Accepted: 16 October 2025
First Online: 20 November 2025
Declarations
:
: KN and AMI reported receiving personal fees from InnoJin, Inc., Outside the submitted work, SN reported grants from Kowa Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Senju Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma KK. TI is the owner of InnoJin Inc., Tokyo, Japan, which developed AllerSearch. Outside the submitted work, TI reports non-financial support from Lion Corporation and Sony Network Communications Inc.; grants from Yuimedi Inc., ROHTO Pharmaceutical Co., Ltd., Kobayashi Pharmaceutical Co., Ltd., and Kandenko Co., Ltd.; and personal fees from Santen Pharmaceutical Co., Ltd. and InnoJin Inc. The remaining authors declare no competing interests.
